-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019
The PRAC starts a new review on screening patients before treatment with fluorouracil, capecitabine, tegafur and flucytosine to decrease risk of side effects.
-
EMA now operating from Amsterdam
EMA now operating from Amsterdam
-
EMA now operating from Amsterdam
EMA now operating from Amsterdam
EMA is now operating from Amsterdam. EMA left its London premises on 1 March, and following a transitional week of teleworking, its staff will gradually move throughout this week into the Spark building in Amsterdam Sloterdijk.
-
From lab to patient: the journey of a centrally authorised medicine
From lab to patient: the journey of a centrally authorised medicine
-
From lab to patient: the journey of a centrally authorised medicine
From lab to patient: the journey of a centrally authorised medicine
EMA has published a booklet describing the journey of a medicine for human use authorised through EMA, from initial research to discussions on patient access to medicines across the EU.
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
EMA and the European Commission provide additional information to help pharmaceutical companies prepare for the UK’s withdrawal from the EU.
